Cargando…

Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer

BACKGROUND: Prostate cancer (PCa) is the second most common type of cancer and the fifth leading cause of cancer-related death in men. Androgen deprivation therapy (ADT) has become the first-line therapy for inhibiting PCa progression; however, nearly all patients receiving ADT eventually progress t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yuezheng, Wang, Haoyu, Pan, Yang, Wang, Shangren, Zhang, Zhexin, Zhou, Hang, Xu, Mingming, Liu, Xiaoqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10151815/ https://www.ncbi.nlm.nih.gov/pubmed/37143720 http://dx.doi.org/10.3389/fendo.2023.1125299

Ejemplares similares

Metabolic syndrome-related prognostic index: Predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer
por: Ren, Congzhe, et al.
Publicado: (2023)

Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis
por: Chen, Xiangyu, et al.
Publicado: (2023)

Identifying hub genes and common biological pathways between COVID-19 and benign prostatic hyperplasia by machine learning algorithms
por: Zhou, Hang, et al.
Publicado: (2023)

Long noncoding RNAs regulated spermatogenesis in varicocele‐induced spermatogenic dysfunction
por: Wang, Shangren, et al.
Publicado: (2022)

Identification and validation of immune and oxidative stress-related diagnostic markers for diabetic nephropathy by WGCNA and machine learning
por: Xu, Mingming, et al.
Publicado: (2023)

Identification of Key microRNAs in Diabetes Mellitus Erectile Dysfunction Rats with Stem Cell Therapy by Bioinformatic Analysis of Deep Sequencing Data
por: Kang, Jiaqi, et al.
Publicado: (2022)

The ERα-NRF2 signalling axis promotes bicalutamide resistance in prostate cancer
por: Tian, Lei, et al.
Publicado: (2022)

Novel biomarkers predict prognosis and drug-induced neuroendocrine differentiation in patients with prostate cancer
por: Lin, Jingwei, et al.
Publicado: (2023)

Whole-gland high-intensity focused ultrasound ablation and transurethral resection of the prostate in the patients with prostate cancer: A systematic review and meta-analysis
por: Pan, Yang, et al.
Publicado: (2022)

Spectrophotometric Estimation of Bicalutamide in Tablets
por: Sancheti, P. P., et al.
Publicado: (2008)

Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer
por: Kandil, Sahar B., et al.
Publicado: (2020)

Comparative efficacy of olaparib in combination with or without novel antiandrogens for treating metastatic castration-resistant prostate cancer
por: Chen, Xiangyu, et al.
Publicado: (2023)

Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models
por: SQUILLACE, RACHEL M., et al.
Publicado: (2012)

Bicalutamide Activated Oncolytic Adenovirus for the Adjuvant Therapy of High Risk Prostate Cancer
por: Johnson, Tamara Jane, et al.
Publicado: (2013)

Compression-Induced Phase Transitions of Bicalutamide
por: Szafraniec-Szczęsny, Joanna, et al.
Publicado: (2020)

Identification of fibroblast-related genes based on single-cell and machine learning to predict the prognosis and endocrine metabolism of pancreatic cancer
por: Xu, Yinghua, et al.
Publicado: (2023)

Association of serum 25-hydroxyvitamin D with urinary incontinence in elderly men: evidence based on NHANES 2007-2014
por: Liu, Li, et al.
Publicado: (2023)

A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer
por: Wang, Yuliang, et al.
Publicado: (2022)

A combined signature of glycolysis and immune landscape predicts prognosis and therapeutic response in prostate cancer
por: Guo, Tao, et al.
Publicado: (2022)

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

Identification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning
por: Xiao, Yingqi, et al.
Publicado: (2022)

Identification of a basement membrane-related gene signature for predicting prognosis and estimating the tumor immune microenvironment in breast cancer
por: Cai, Jiehui, et al.
Publicado: (2022)

Elafin is related to immune infiltration and could predict the poor prognosis in ovarian cancer
por: Lu, Weiyu, et al.
Publicado: (2023)

Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014)

A case of advanced prostate cancer controlled for the long term by flutamide after bicalutamide failure
por: Muramatsu, Tomoaki, et al.
Publicado: (2019)

Successful recovery from multiple organ failure associated with bicalutamide and leuprorelin acetate for prostate cancer
por: Saito, Seiichi
Publicado: (2019)

Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma
por: Guo, Zhaoxin, et al.
Publicado: (2022)

Leiomyoma of the prostate: A case report and systematic review
por: Wang, Shangren, et al.
Publicado: (2022)

Identification of the alpha linolenic acid metabolism-related signature associated with prognosis and the immune microenvironment in nasopharyngeal carcinoma
por: Fang, Zhijie, et al.
Publicado: (2022)

Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

Sirtuins and Insulin Resistance
por: Zhou, Shuang, et al.
Publicado: (2018)

Bicalutamide-induced hepatotoxicity: A rare adverse effect
por: Hussain, Salwa, et al.
Publicado: (2014)

Mesotherapy with Bicalutamide: A New Treatment for Androgenetic Alopecia
por: Gomez-Zubiaur, Alba, et al.
Publicado: (2023)

The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysis
por: Dijkstra, Siebren, et al.
Publicado: (2016)

Identification of markers for predicting prognosis and endocrine metabolism in nasopharyngeal carcinoma by miRNA–mRNA network mining and machine learning
por: Zhang, Xixia, et al.
Publicado: (2023)

Prophylactic Breast Bud Radiotherapy for Patients Taking Bicalutamide: Should This Still Be Practised for Patients with Prostate Cancer?
por: Lewis, R., et al.
Publicado: (2012)

CCNB1 and AURKA are critical genes for prostate cancer progression and castration-resistant prostate cancer resistant to vinblastine
por: Chen, Xi, et al.
Publicado: (2022)

The Use of High-Intensity Focused Ultrasound (HIFU) Plus 150mg Bicalutamide as First Line Salvage Therapy for Local Recurrent Prostate Cancer
por: Cao, Jian-zhou, et al.
Publicado: (2021)

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide
por: Nakai, Yasushi, et al.
Publicado: (2018)

Identification of a pyroptosis-related lncRNA signature in the regulation of prognosis, metabolism signals and immune infiltration in lung adenocarcinoma
por: Zhou, Shuyi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9mvv4ufa4q0n97t4r97msfu7r4